The formation of Aβ peptide requires the initial cleavage of Amyloid Precursor Protein (APP) by the transmembrane aspartyl protease BACE1 (β-site APP cleaving enzyme 1), which is one of the major therapeutic targets being currently explored for an AD-modifying intervention. The gene discussed is APP; the disease is Alzheimer disease.